(Q53661913)

30 June 2019

title

Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. (English)

1 reference

30 June 2019

main subject

cardiovascular disease

1 reference

Yu Xie

1

1 reference

30 June 2019

William J Collins

2

1 reference

30 June 2019

M William Audeh

3

1 reference

30 June 2019

Stephen L Shiao

4

1 reference

30 June 2019

Roberta A Gottlieb

5

1 reference

30 June 2019

Marc T Goodman

6

1 reference

30 June 2019

C Noel Bairey Merz

7

1 reference

30 June 2019

Puja K Mehta

8

1 reference

30 June 2019

publication date

1 December 2015

1 reference

30 June 2019

Current treatment options in cardiovascular medicine

published in

1 reference

30 June 2019

volume

17

1 reference

30 June 2019

page(s)

60

1 reference

30 June 2019

issue

12

1 reference

30 June 2019

https://scigraph.springernature.com/pub.10.1007/s11936-015-0421-y

exact match

0 references

cites work

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Doxorubicin-induced apoptosis: implications in cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Early breast cancer therapy and cardiovascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Cancer genetics and the cardiotoxicity of the therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Risk of ischemic heart disease in women after radiotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Distribution of coronary artery stenosis after radiation for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Is there a dose-response relationship for heart disease with low-dose radiation therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Noninvasive methods for the early detection of doxorubicin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Normal ranges of left ventricular strain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Exercise training improves cardiopulmonary and endothelial function in women with breast cancer: findings from the Diana-5 dietary intervention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Exercise training improves heart rate recovery in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Cardiac troponin I levels in patients with non-ST-elevation acute coronary syndrome-the importance of gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Gender-specific differences in biomarkers responses to acute coronary syndromes and revascularization procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Pharmacology of carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Protective effects of spironolactone against anthracycline-induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-015-0421-Y

Echocardiographic evaluation of adriamycin cardiotoxicity in children

21 January 2018

1 reference

12 December 2020

Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy

1 reference

12 December 2020

Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice.

1 reference

12 December 2020

Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature

1 reference

12 December 2020

Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential

1 reference

12 December 2020

Exercise capacity and the risk of death in women: the St James Women Take Heart Project

1 reference

12 December 2020

Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity

1 reference

12 December 2020

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Late Cardiac Mortality and Morbidity in Early-Stage Breast Cancer Patients After Breast-Conservation Treatment

1 reference

12 December 2020

Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy

1 reference

12 December 2020

Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

1 reference

12 December 2020

Subendocardial ischemia and myocarditis in systemic lupus erythematosus detected by cardiac magnetic resonance imaging

1 reference

12 December 2020

Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management

1 reference

12 December 2020

Trastuzumab containing regimens for early breast cancer

1 reference

12 December 2020

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

1 reference

12 December 2020

Exercise interventions on health-related quality of life for people with cancer during active treatment

1 reference

12 December 2020

Sex-specific cutoffs for cardiac troponin using high-sensitivity assays--Is there clinical equipoise?

1 reference

12 December 2020

Chemotherapy-related Cardiomyopathy

1 reference

12 December 2020

A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin

1 reference

12 December 2020

Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals

1 reference

12 December 2020

Mitochondria-mediated cell injury. Symposium overview

1 reference

12 December 2020

10.1007/S11936-015-0421-Y

Identifiers

DOI

1 reference

30 June 2019

PMCID

6364685

1 reference

30 June 2019

PubMed ID

26490280

1 reference

30 June 2019